Form 4: Quest Diagnostics Executive Sam Samad Reports Acquisition of Shares
SEC Filing
Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquisition of common stock and restricted share units.
Summary
- Sam Samad, Executive Vice President & CFO of Quest Diagnostics, filed a Form 4.
- The filing reports the acquisition of 24 shares of common stock at a price of $126.245 on April 22, 2024, through a dividend reinvestment plan.
- It also reports an award of restricted share units.
- Following the reported transactions, Samad beneficially owns 21,356 shares.
- The reporting person has chosen to report such transaction early on this Form 4.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reports routine transactions. The acquisition of shares through a dividend reinvestment plan could be seen as slightly positive, indicating confidence.
Positives
- The acquisition of shares through a dividend reinvestment plan demonstrates confidence in the company's future.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The reported transactions provide transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 04/22/2024 | Date of common stock acquisition and restricted share unit award. |
| 04/26/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.